ImmunityBio, Inc. (IBRX) Financials
IBRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 504.5 million | 1.1 billion |
2023-09-30 | 432.4 million | 843.1 million |
2023-06-30 | 291.2 million | 936.4 million |
2023-03-31 | 343.4 million | 875.1 million |
IBRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -123.2 million | 12.8 million |
2023-09-30 | -93.1 million | 14.4 million |
2023-06-30 | -88.3 million | 11.1 million |
2023-03-31 | -92.7 million | 10.9 million |
IBRX Net Income
No data available :(
IBRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 266.5 million | - | 45.2 million |
2023-09-30 | 189.8 million | - | 43.7 million |
2023-06-30 | 46.0 million | - | 50.5 million |
2023-03-31 | 91.3 million | - | 49.1 million |
IBRX Shares Outstanding
IBRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 8.0 million | 51.0 million | 33.1 million | - |
2023-09-30 | 5.7 million | 48.4 million | 31.8 million | - |
2023-06-30 | 8.5 million | 53.2 million | 32.0 million | - |
2023-03-31 | 8.4 million | 79.3 million | 32.7 million | - |
IBRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 139000 | 4.6 million |
2023-09-30 | 82000 | 4.6 million |
2023-06-30 | 41000 | 6.3 million |
2023-03-31 | 360000 | 6.3 million |
IBRX
Price: $9.15
52 week price:
Earnings Per Share: -1.15 USD
P/E Ratio: -4.40
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.2 million
Market Capitalization: 4.1 billion